Autistic Spectrum Disorder Clinical Trial
Official title:
Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study
This study is a phase II, prospective, double blind, placebo-controlled study of the efficacy of autologous umbilical cord blood infusion. The study population will consist of 60 children ages 18 months to 12 years with ASD. The population will be randomly assigned to 2 groups, the study group be treated by cord blood in the beginning of the study and the control group by placebo product. The study will consist of 4 stages Stage 1: initial assessment by physiotherapist and occupational therapist / treatment by cord blood or placebo / blood work before and after treatment Stage 2: at stage 1 + 6 months assessment by physiotherapist and occupational therapist / cross-over treatment by cord blood or placebo / blood work before and after treatment Stage 4: at stage 1 + 12 months assessment by physiotherapist and occupational therapist The primary outcome is improvement of social communication skills six months after treatment at stage 1
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Months to 12 Years |
Eligibility | Inclusion Criteria: - Age = 1.5 years to = 12 years (11 years, 364 days) at the time of visit 1 - Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using the DSM-5 criteria - Fragile X testing performed and negative - Available and qualified umbilical cord blood unit with a minimum banked total nucleated cell dose of = 2 x 10e7 cells/kg - Stable on current psychiatric medication regimen (dose and dosing schedule) for at least 2 months prior to infusion of study product - Normal absolute lymphocyte count (=1500/uL) - Able to travel to Sheba Medical Center University three times (baseline, 6 and 12 months post-baseline), and parent/guardian is able to participate in interim surveys and interviews monthly - Parental consent Exclusion Criteria - General: - Review of medical records indicates ASD diagnosis not likely - Known diagnosis of any of the following coexisting psychiatric conditions: depression, bipolar disorder, schizophrenia, obsessive compulsive disorder - Screening data suggests that participant would not be able to comply with the requirements of the study procedures, including study outcome measures, as assessed by the study team - Family is unwilling or unable to commit to participation in all study-related assessments, including follow up for approximately 12 months - Genetic: - Records indicate that child has a known genetic syndrome such as (but not limited to) Fragile X syndrome, neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cystic fibrosis, muscular dystrophy - Known pathogenic copy number variation (CNV) associated with ASD (e.g., 16p11.2, 15q13.2, 2q13.3) - Infectious: - Known active CNS infection - Evidence of uncontrolled infection based on records or clinical assessment - HIV positivity - 4 Medical: - Known metabolic disorder - Known mitochondrial dysfunction - History of unstable epilepsy or uncontrolled seizure disorder, Lennox Gastaut syndrome, Dravet syndrome, or other similar epileptic encephalopathy - Concurrent genetic or acquired disease or comorbidity(ies) that could require a future stem cell transplant - Significant sensory (e.g., blindness, deafness, uncorrected hearing impairment) or motor (e.g., cerebral palsy) impairment - Evidence of clinically relevant physical dysmorphology indicative of a genetic syndrome as assessed by the PIs or other investigators, including a medical geneticist and psychiatrists trained in identifying dysmporphic features associated with neurodevelopmental conditions. - Current/Prior Therapy: - History of prior cell therapy - Current or prior use of IVIG or other anti-inflammatory medications with the exception of NSAIDs - No systemic steroid therapy that has lasted >2 weeks, and no systemic steroids within 3 months prior to enrollment. Topical and inhaled steroids are permitted. |
Country | Name | City | State |
---|---|---|---|
Israel | Chaim Seba Medical Center | Ramat Gan |
Lead Sponsor | Collaborator |
---|---|
Sheba Medical Center |
Israel,
Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Lee LC, Pettygrove S, Robinson C, Schulz E, Wells C, Wingate MS, Zahorodny W, Yeargin-Allsopp M; Centers for Disease Control and Prevention (CDC). Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years--Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ. 2016 Apr 1;65(3):1-23. doi: 10.15585/mmwr.ss6503a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2016;65(15):404. — View Citation
Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014 Mar 8;383(9920):896-910. doi: 10.1016/S0140-6736(13)61539-1. Epub 2013 Sep 26. Review. — View Citation
Prata J, Santos SG, Almeida MI, Coelho R, Barbosa MA. Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations. J Neuroinflammation. 2017 Sep 4;14(1):179. doi: 10.1186/s12974-017-0938-y. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of social communication skills | Vineland Adaptive Behavior Scales-Second Edition (VINELAND-II) | 6 months | |
Primary | Improvement of social communication skills | Pediatric Evaluation of Disability Inventory-Computer Adaptive Test-ASD | 6 months | |
Secondary | Improvement of social communication skills | Theory of Mind Inventory - 2 | 6 months | |
Secondary | Functional assessment | Adaptive Behavior Assessment System - Second edition (ABAS-2) | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05497167 -
Development and Evaluation of "Period Kits" for Adolescents With Intellectual and Developmental Disabilities
|
N/A | |
Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
Completed |
NCT06086964 -
Effect of Therapeutic Diet With Physiotherapy on Gross Motor and Cognition of Autistic Children
|
N/A | |
Not yet recruiting |
NCT05302544 -
Impact of Mixed Reality Training on Motor Skills in Children With Autistic Spectrum Disorder
|
N/A | |
Completed |
NCT03957044 -
the Effect of Vestibular Rehabilitation in Autistic Children
|
N/A | |
Recruiting |
NCT06272669 -
Cumulative and Booster Effects of Multisession Prefrontal tDCS in Adolescents With ASD
|
N/A | |
Recruiting |
NCT05492032 -
Cumulative and Booster Effects of Multisession Prefrontal tDCS in Adolescents With ASD
|
N/A | |
Completed |
NCT02057809 -
"Family-centered" Pediatric Rehabilitation Services in Children With Developmental Disabilities
|
||
Completed |
NCT04007224 -
Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder
|
Phase 1 | |
Completed |
NCT05077020 -
Somatic Diseases in Autistic Children
|
||
Completed |
NCT05025553 -
Oral Administration of Polyethylene Glycol (PEG) for 6 Months in Chronically Constipated Autistic Children
|
N/A | |
Completed |
NCT04261595 -
Dates as a Functional Food for Autism
|
N/A | |
Completed |
NCT05515913 -
Nutritional Status and ASD Severity of Autistic Spectrum Disorder Children in Addis Ababa, Ethiopia; Case Control Study
|
||
Completed |
NCT05875363 -
Neurodevelopmental Disorders in Youth With Criminal Behaviors
|